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Abstract
Objectives Liver-specific MRI is a fast-growing field, with
technological and protocol advancements providing more ro-
bust imaging and allowing a greater depth of information per
examination. This article reports the evidence for, and expert
thinking on, current challenges in liver-specific MRI, as
discussed at the 7th International Forum for Liver MRI, which
was held in Shanghai, China, in October 2013.
Methods Topics discussed included the role of gadoxetic
acid-enhanced MRI in the differentiation of focal nodular hy-
perplasia from hepatocellular adenoma and small hepatocel-
lular carcinoma (HCC) from small intrahepatic cholan-
giocarcinoma (in patients with chronic liver disease),
the differentiation of low-grade dysplastic nodule (DN)
from pre-malignant high-grade DN and early HCC, and
treatment planning and assessment of treatment response
for patients with HCC and colorectal liver metastasis.
Optimization of the gadoxetic acid-enhanced MRI pro-
tocol to gain robust arterial and hepatobiliary phase im-
ages was also discussed.
Results and conclusions Gadoxetic acid-enhanced MRI dem-
onstrates added value for the detection and characterization of
focal liver lesions and shows promise in a number of new
indications, including regional liver functional assessment
and patient monitoring after therapy; however, more data are
needed in some areas, and further developments are needed to
translate cutting-edge techniques into clinical practice.
Key Points
• Liver-specific MRI is a fast-growing field, with many tech-
nological and protocol advancements.
• Gadoxetic acid-enhanced MRI demonstrates value for de-
tecting and characterizing focal liver lesions.
• Gadoxetic acid-enhanced MRI shows promise in regional
functional assessment and patient monitoring.
• Further developments are needed to translate cutting-edge
techniques into clinical practice.
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Introduction
There is growing evidence for the benefits of gadoxetic-
acid-enhanced magnetic resonance imaging (MRI) in a
number of indications for liver imaging. Topics in this
area were discussed by more than 70 international ab-
dominal experts at the 7th International Forum for Liver
MRI, held in Shanghai, China, in October 2013. Forum
participants attended presentations by the authors of this
article on the following related topics and discussed
these data further in four workgroups:
1. Liver lesion characterization – challenging differential
diagnoses
2. Differentiation of low-grade dysplastic nodule (DN) from
pre-malignant high-grade DN and early hepatocellular
carcinoma (HCC)
3. The role of Primovist® in treatment planning and assess-
ment of treatment response
4. Tips and tricks session – how to improve imaging with
Primovist® – differences versus traditional agents
Consensus statements on each topic were proposed based
on available evidence and expert opinions of participants. The
whole forum further discussed, amended, and voted on the
statements, using an electronic voting system with the options
‘agree’, ‘disagree’ or ‘abstain’. The final consensus statements
and the voting results are presented in this article, with the
intent to inform radiologists and assist them in their daily
clinical practice.
Challenging differential diagnoses in liver lesion
characterization
Focal nodular hyperplasia (FNH) and hepatocellular
adenoma (HCA)
FNH and HCA are benign hepatocellular tumours; dif-
ferentiating is important because FNHs are usually man-
aged conservatively, while HCAs are managed accord-
ing to risk of spontaneous bleeding and malignant trans-
formation [1]. Distinguishing between FNH and HCA
using dynamic contrast-enhanced (CE) computed tomog-
raphy (CT) or MRI can be challenging when hallmark
features (e.g. central scar) are absent, due to overlapping
imaging features.
Consensus statement 1.1 The hepatobiliary phase (HBP) of
gadoxetic acid-enhanced MRI can help in the differential di-
agnosis of FNH and HCA. Specifically, hyperintensity or
isointensity relative to the liver, which may be diffuse
or per iphera l , favours FNH. Del inea t ion of a
hypointense central scar strongly favours FNH. Diffuse
hypointensity relative to the liver strongly favours HCA.
[67/69 (97.1 %) agreement]
The HBP imaging features of FNH on gadoxetic acid-
enhanced MRI commonly include iso- or hyperenhancement
in the HBP (largely strong homogeneous enhancement) [1–4],
with hypoenhancement of any central scar relative to the rest
of the lesion on T2-weighted images [1]. On the other hand,
for HCA, hypointensity in the HBP, relative to the surround-
ing liver parenchyma, is common [2, 5, 6]. Recent evidence
suggests that the HBP of gadoxetic acid-enhanced MRI has a
sensitivity and positive predictive value (PPV) of 96 % for
differentiation of FNH and HCA [7], and may increase correct
lesion diagnosis and reader confidence versus unenhanced
and dynamic images alone [8].
Consensus statement 1.2 Further research is needed to de-
termine the role of the HBP of gadoxetic acid-enhanced MRI
in predicting HCA subtype. [71/73 (97.3 %) agreement]
Only a few studies [5, 9, 10] are currently available to
assess the value of HBP images from gadoxetic-acid-
enhancedMRI in differentiating HCA subtypes; however, up-
take in the HBP appears to be useful additional information.
Small intrahepatic cholangiocarcinoma (ICC) and HCC
in patients with chronic liver disease
Patients with liver cirrhosis or chronic hepatitis are at
risk of developing malignant liver lesions – most com-
monly HCC, but also ICC. Differential diagnosis is im-
portant, as prognoses and patient management differ
[11, 12]. Using extracellular agents, portal venous and
delayed-phase images help in the differentiation; pro-
gressive or sustained concentric enhancement favours
ICC, whereas diffuse or nodular washout appearance
favours HCC. Using gadoxetic acid, the differential di-
agnosis is more difficult as both lesions typically are
hypointense in the hepatobiliary phase. Therefore, recent
retrospective studies have attempted to identify discrim-
inatory imaging features using gadoxetic acid.
Consensus statement 1.3 In patients at increased risk for
HCC with small nodules (<3 cm) that are suspicious
for malignancy but lack hallmark imaging features of
HCC, reliable differentiation between HCC and ICC
may not be possible.
Gadoxetic acid-enhanced MRI features that favour ICC
over HCC include:
& lobulated shape
& rim enhancement in the arterial phase
& target appearance on diffusion-weighted images
& target appearance in the HBP
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Gadoxetic acid-enhanced MRI features that favour HCC
over ICC include:
– intralesional fat
– diffuse hyperintensity on pre-contrast T1-weighted
imaging
– nodule-in-nodule architecture
– diffuse hyperintensity relative to liver in the HBP
[63/72 (87.5 %) agreement]
Consensus statement 1.4 Prospective studies in consecutive
patients are needed to refine and validate gadoxetic acid-
enhanced MRI features for differentiation of small ICC and
HCC in patients at increased risk for HCC. [62/72 (87.5 %)
agreement]
Univariate analyses of imaging features in gadoxetic-acid-
enhancedMRI that were predictive of ICC over HCC revealed
significance (P≤0.005) for lobulated shape, arterial phase rim
enhancement, target appearance in the HBP (central
hyperintensity with a peripheral hypointense rim on the
10- or 20-min images) and target diffusion-weighted
imaging (DWI) appearance (central hypointensity and
peripheral hyperintensity on b=800 s/mm2 images)
(Fig. 1); however, only target appearance on DWI
remained significant in multivariate analyses [13]. Other
studies reported lobulated shape, arterial phase rim en-
hancement and target HBP appearance in varying pro-
portions of ICCs, thus these features are suggestive, but
not conclusive, of ICC [14–19].
A l t hough uncommon , imag ing f e a t u r e s on
gadoxetic-acid-enhanced MRI that are suggestive of
HCC in patients with chronic liver disease include
d i f f u s e h y p e r i n t e n s i t y i n t h e HBP, d i f f u s e
hyperintensity on pre-contrast T1-weighted images,
presence of intralesional fat and a nodule-in-nodule
appearance [20, 21]. To our knowledge, these MRI
features have not been described for ICC before. Fur-
thermore, intralesional fat and nodule-in-nodule ap-
pearance are not included in the WHO’s description
of ICC pathology [22].
Differentiation of low-grade DN from pre-malignant
high-grade DN and early HCC
Detection of pre-malignant nodules and early HCCs in pa-
tients with chronic liver disease improves the chances of cu-
rative treatment as progression after radiofrequency ablation
(RFA) is less frequent in hypovascular versus hypervascular
small HCC [23, 24]. On CE-MRI, these pre-malignant nod-
ules often lack the hallmark imaging features of HCC and
pose a diagnostic challenge.
Consensus statement 2.1 Hypointensity in the HBP of
gadoxetic acid-enhanced MRI provides high sensitivity for
the detection of iso-/hypovascular pre-malignant (HGDN)
and malignant (eHCC) hepatocellular lesions; however, dif-
ferentiation of these lesions is not currently possible. [67/73
(91.8 %) agreement]
Consensus statement 2.2 Gadoxetic acid-enhanced MRI, in-
corporating a combination of ancillary features (lesion size,
lesion growth, T2 intensity, DWI, T1 intensity, HBP intensity
and intralesional fat), improves risk stratification of patients
with chronic liver disease and lesions without hallmark vas-
cular features of HCC. [51/57 (89.5 %) agreement]
Progression of pre-malignant/early HCC has been linked to
s ize (>1 cm) [25–30] , and an increased r isk of
hypervascularization is associated with the presence of fat
(P<0.01), enlargement during follow-up (P=0.04), T2
hyperintensity (P=0.06) [29, 31] and hyperintensity on
DWI [31].
Hypointensity in the HBP of gadoxetic acid-enhancedMRI
is suggestive of pre-malignancy ormalignancy (irrespective of
lesion vascularity) and can increase the sensitivity of diagno-
sis [32], with almost all HCC and some high-grade DNs being
hypointense in this phase [33]. While some low-grade DNs
and regenerative nodules (RNs) also show hypointensity in
the HBP [34, 35], these nodules are usually <1 cm [36], while
high-grade DN and early HCC tend to be >1 cm. Enhance-
ment ratios for gadoxetic acid decreased with nodule differen-
tiation, but are unable to distinguish between DN and
hypovascular well differentiated HCC due to considerable
overlap [35, 37].
The role of gadoxetic acid-enhanced MRI
in treatment planning and assessment of treatment
response
Pre-operative diagnosis and staging of liver lesions
Wider use of local treatments and more aggressive surgical
options require more meticulous pre-operative planning,
alongside volume-based functional analyses [38, 39].
Gadoxetic acid-enhanced MRI can provide comprehensive
morphological and regional functional information in a single
examination and is showing promise as a pre-operative assess-
ment tool.
Colorectal liver metastases (CRLM)
Hepatic metastases occur in more than half of patients with
primary colorectal cancer [40]. Around 20–25 % of patients
with CRLM will present with resectable disease [40, 41]. Pa-
tient selection and therapy planning may be improved by
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better estimation of liver remnant function, and by accurate
detection and staging of tumours.
Consensus statement 3.1 Evidence and experience suggest
that gadoxetic acid-enhanced MRI combined with DWI is the
most accurate imaging modality for preoperative diagnosis of
CRLM. [54/66 (81.8 %) agreement]
Estimation of segmental liver function using MRI, based
on hepatic uptake of gadoxetic-acid, has shown good correla-
tion with conventional measures of function, and with disease
severity scoring systems [27, 42–44]. Gadoxetic-acid-
enhanced MRI has shown a high sensitivity and PPV (96 %
and 0.91, respectively) for the pre-operative work-up of pa-
tients with CRLM (superior to bothMDCTand positron emis-
sion tomography [PET]/CT) [45], and was more sensitive than
MDCT for the detection of histopathologically proven
CRLM, especially those <1 cm [46]. Combining gadoxetic-
acid-enhanced MRI with DWI appears to further improve the
detection of CRLM compared with the individual imaging
techniques [47, 48], especially for small metastases [49], in-
cluding patients who have undergone pre-operative chemo-
therapy [50].
Hepatocellular carcinoma (HCC)
International guidelines on HCC management recommend
stratification of treatment into potentially curative and pallia-
tive therapies according to the severity of underlying liver
disease and the number, size and invasiveness of hepatic nod-
ules [51, 52].
Consensus statement 3.2 Increasing evidence suggests that
gadoxetic acid-enhanced MRI combined with T2-weighted
imaging and DWI is an accurate method for the diagnosis
and staging of HCC. [63/68 (92.6 %) agreement]
According to the current guidelines, multiphasic MDCT
and MRI with extracellular contrast agents are the first-line
imaging modalities to characterize lesions in patients at risk
for development of HCC. However, features like
hyperintensity in DWI and hypointensity in HBP images are
considered as valuable contributions to the vascular assess-
ment of such lesions.
Gadoxetic-acid-enhanced MRI has high sensitivity for
the diagnosis of HCC, especially those ≤2 cm [34,
53–57], and is more sensitive than MDCT for detecting
HCC ≤1 cm [58]. Pre-operative detection of additional
very small liver lesions (potentially leading to recur-
rence) may change the proposed therapy and increase
the chance of curative treatment [59].
DWI increases the detection rate of focal liver lesions com-
pared with breath-hold T2-weighted MRI alone [60]. One
recent study showed that on MDCT 64/102 (63 %) small
(≤2 cm) HCCs showed a target appearance, while 13 (13 %)
were not detected [61]. In contrast, 84 (82 %) HCCs demon-
strated target arterial hyperintensity, HBP hypointensity and
DWI hyperintensity on gadoxetic acid-enhanced MRI, and a
further eight hypovascular HCCs could be identified as hyper-
intense lesions on DWI [61].
Assessment of the liver following non-surgical treatment
of liver malignancies
Locoregional therapies are recommended when surgical re-
section or transplantation are not options for malignant liver
lesions [51, 62, 63]. Subsequent assessment of the liver in-
volves evaluation of therapeutic success, liver injury as a re-
sult of the treatment, and detection of recurrence.
Consensus statement 3.3 Gadoxetic acid-enhanced MRI
shows promise for assessment of radiation-induced liver inju-
ry. [61/67 (91.0 %) agreement]
R e d u c e d g a d o x e t i c - a c i d u p t a k e ( d i f f u s e
hypointensity on HBP images) following interstitial
brachytherapy correlates with radiation dose-related
Fig. 1 Target appearance of
intrahepatic cholangiocarcinoma
on gadoxetic acid-enhanced MRI
and diffusion-weighted imaging.
Images courtesy of Claude Sirlin
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hepatocyte dysfunction [64], and subsequent repair of
the parenchyma post-therapy is evident as a reduced
area of hypointensity [65]. Thus, gadoxetic-acid-
enhanced MRI can be used to detect parenchymal dam-
age and assess the value of protective therapies [66]. In
addition, the dose range of proton therapy can be sim-
ilarly assessed [67].
Consensus statement 3.4 Gadoxetic acid-enhanced MRI is
useful for follow-up after local and locoregional therapy of
HCC with respect to the assessment of new lesions, but the
value of the HBP is questionable for the assessment of local
control after thermal ablation in early follow-up. [55/67
(82.1 %) agreement]
Evaluation of sensitivity, specificity and accuracy of
unenhanced T1-weighted, T2-weighted and dynamic
gadoxetic acid-enhanced MRI to detect HCC recurrence fol-
lowing radiofrequency ablation of the liver showed similar
results; addition of HBP images did not improve these results
[68]. In many cases, HBP hypointensity due to reactive ther-
apeutic responses around the treated lesion could not be dis-
tinguished from tumour recurrence.
Evaluation of liver dysfunction after liver transplant
Dysfunction in transplanted livers following orthotropic
liver transplantation (OLT) may involve structural com-
plications (vascular or biliary complications, HCC recur-
rence, lymphoproliferative disorder) or more diffuse
conditions (acute and chronic rejection, cold ischaemia,
recurrent viral hepatitis, autoimmune hepatitis, fibrosis,
cirrhosis) [69, 70]. These conditions are commonly
assessed using a combination of serum liver function
tests and imaging [70].
Consensus statement 3.5 Preliminary data show a correla-
tion between parenchymal dysfunction and gadoxetic acid
uptake and excretion in post-liver transplantation patients.
This could play a future role in monitoring OLT dysfunction,
and further investigation is warranted. [59/68 (86.8 %)
agreement]
Gadoxetic acid-enhanced MRI is a promising tool for re-
gional liver function assessment [27, 42, 43] and may be a
useful, non-invasive, prognostic biomarker for chronic liver
graft rejection and patient outcome [71]. Liver transplant re-
cipients with impaired hepatobiliary excretion of gadoxetic-
acid showed significantly higher median serum bilirubin
levels (4.9 vs. 1.2 mg/dL, P<0.001), aspartate aminotransfer-
ase (89 vs. 41 IU/L, P=0.003) and alkaline phosphatase (322
vs. 143 IU/L, P=0.007), and within 1 year, 11/20 patients died
or required re-transplantation, while all 31 patients with nor-
mal gadoxetic acid excretion survived without re-
transplantation (P<0.001) [71].
In a recent study [72], a significant correlation was
found between relative liver enhancement (RLE) at
20 min and liver failure in retrospective univariate and
multivariate analyses in 73 patients who underwent
gadoxetic-acid-enhanced MRI prior to resection of three
or more liver segments. Pre-operative RLE was inverse-
ly related to the probability of post-operative liver fail-
ure [72]. The probability of liver failure was close to
zero for a RLE >100 %, suggesting that an RLE of
100 % may be a cut-off to predict patients at risk for
liver failure. However, determination of cut-off values
must be viewed cautiously and more data is needed to
validate these values.
Tips and tricks to optimize imaging with gadoxetic
acid-enhanced MRI
Arterial phase imaging
Gadoxetic acid differs from extracellular MR-contrast media
in that it has higher T1 relaxivity [73], and is formulated at half
of the gadolinium concentration with a recommended quarter
standard dose (0.025 mol/kg body weight) in half the standard
injected volume. Working with a compact bolus can be chal-
lenging, but strategies to ensure robust arterial phase imaging
are available.
Consensus statement 4.1 Artefacts observed in gadoxetic
acid-enhanced MRI in the arterial phase can be reduced by
using multiphase pulse sequences with short acquisition
times. [58/64 (90.6 %) agreement]
Consensus statement 4.2 Ancillary strategies for reducing
arterial phase artefacts include stretching the contrast bolus,
sequential k-space filling and patient-tailored timing of the
hepatic arterial phase acquisition. [62/64 (96.9 %) agreement]
Artefacts seen in the arterial phase of CE-MRI include
breathing or motion artefacts, truncation artefacts and phase
ghosting (due to rapid change of gadolinium concentration
during k-space acquisition) [74]. Breathing artefacts can be
reduced by good patient instructions. Both breathing and trun-
cation artefacts can be addressed by shortening the acquisition
time, for example by acquiring multiple short arterial phase
sequences rather than a single longer one. In this way, at least
one phase will likely coincide with optimal arterial enhance-
ment, and transient artefacts (e.g. due to motion) may contam-
inate only one of the acquired phases [75]. Truncation or
phase-ghosting artefacts can also be reduced by stretching
the contrast bolus [76–80]. Furthermore, timing of the contrast
bolus can be improved with semiautomated, bolus-triggered
techniques.
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Hepatobiliary phase imaging
Technique optimization
The signal-to-noise ratio (SNR) of hepatobiliary contrast en-
hancement is related to the concentration of CM in the target
tissue and the strength of T1 weighting.
Consensus statement 4.3 For gadoxetic acid-enhanced HBP
liver MRI, optimized pulse sequences using high flip angles
can improve liver lesion conspicuity and detection. [60/66
(90.1 %) agreement]
Higher flip angles in HBP sequences can increase liver
parenchymal contrast enhancement and improve the conspi-
cuity of lesions [81]. At higher flip angles, sensitivity for le-
sion detection was significantly improved (89.0 % vs. 79.5 %
for small flip angles, P=0.0003), particularly for small (3–
10 mm) lesions (81.4 % vs. 65.7 %, P=0.0002) and the
liver-to-lesion contrast was significantly greater in most large
(≥10mm) lesions (378 vs. 150,P<0.05) [82]. The optimal flip
angle for imaging in the HBP has been suggested to be around
40° [83].
Timing of the hepatobiliary phase
Deciding when to acquire HBP imaging sequences on
gadoxetic-acid-enhanced MRI is generally a compromise be-
tween shorter and longer delays (patient comfort vs. improved
visualization of biliary excretion).
Consensus statement 4.4 The post-injection delay for
hepatobiliary imaging with gadoxetic acid is patient and indi-
cation specific. While a 20-min delay is acceptable in most
cases, a shorter delay may be feasible for parenchymal imag-
ing in some patients. Longer delays may be helpful for biliary
imaging. [61/62 (98.4 %) agreement]
Consensus statement 4.5 The post-injection delay for hepa-
tocyte phase imaging with gadoxetic acid is patient and indi-
cation specific. Longer delays may be helpful for patients with
impaired liver uptake. [53/63 (84.1 %) agreement]
The optimal delay before acquiring HBP images following
gadoxetic acid administration was suggested to be 20 min [84].
Nonetheless, in a variety of patients, adequate HBP images can
be obtained well before 20 min [85–88]. However, HBP en-
hancement occurs later and more weakly in patients with
chronic liver disease, suggesting that a longer delay after injec-
tion of gadoxetic acid may be optimal in such patients [85].
For biliary imaging, the signal intensity of gadoxetic acid
enhancement in the common bile duct reaches a peak at 30-
min post-injection in patients with and without chronic liver
disease (lower signal intensity in patients with liver disease)
[89]. In addition, since gadoxetic acid and bilirubin are taken
up by the same family of organic anion transport proteins
(OATPs), the presence of an elevated serum bilirubin level is
associated with reduced hepatic gadoxetic-acid uptake and
poor enhancement in the hepatobiliary phase [54]. For this
reason, an elevated bilirubin level is a relative contraindication
in some centres for gadoxetic acid, with threshold bilirubin
levels from 2.0–5.0 mg/dL [54, 90].
Summary
Gadoxetic acid-enhanced MRI, including HBP imaging, pro-
vides high sensitivity for differentiating FNH and HCA; how-
ever, the role of the HBP to aid prediction of HCA subtype
requires further research. Specific features of HCC and ICC
demonstrated on gadoxetic acid-enhanced MRI can aiding
differential diagnosis. Hypointensity in the HBP of gadoxetic
acid-enhancedMRI provides high sensitivity for the detection
of pre-malignant hepatocellular lesions, although it is current-
ly not possible to differentiate those. Incorporating a combi-
nation of ancillary MRI findings can assist in patient risk
stratification. Gadoxetic acid-enhanced MRI combined with
DWI may be the most accurate imaging modality for
the pre-operative diagnosis of CRLM. Gadoxetic acid-
enhanced MRI also shows promise for evaluating
radiation-induced liver injury and the occurrence of
new lesions after locoregional therapy, and could play
a role in assessing liver dysfunction after transplanta-
tion. Various techniques can increase the robustness of
gadoxetic acid-enhanced MRI, reduce artefacts and im-
prove lesion conspicuity in HBP images. Post-injection
delays for hepatobiliary imaging with gadoxetic acid are
patient- and indication-specific.
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